138 related articles for article (PubMed ID: 3123547)
1. Pituitary function after orchiectomy in patients with or without earlier estrogen treatment for prostatic carcinoma.
Tomić R
J Endocrinol Invest; 1987 Oct; 10(5):479-82. PubMed ID: 3123547
[TBL] [Abstract][Full Text] [Related]
2. Effect of orchidectomy performed after cessation of estrogen therapy on serum testosterone concentrations in patients with prostatic carcinoma.
Tomić R; Damber JE
Urol Int; 1987; 42(6):441-4. PubMed ID: 3129850
[TBL] [Abstract][Full Text] [Related]
3. Hormonal effects of cessation of estrogen treatment for prostatic carcinoma.
Tomić R; Bergman B
J Urol; 1987 Oct; 138(4):801-3. PubMed ID: 3116281
[TBL] [Abstract][Full Text] [Related]
4. Some effects of orchiectomy, oestrogen treatment and radiation therapy in patients with prostatic carcinoma.
Tomić R
Scand J Urol Nephrol Suppl; 1983; 77():1-37. PubMed ID: 6426040
[TBL] [Abstract][Full Text] [Related]
5. Pituitary-testicular function of prostatic cancer patients during treatment with a gonadotropin-releasing hormone agonist analog. I. Circulating hormone levels.
Huhtaniemi I; Nikula H; Rannikko S
J Androl; 1987; 8(6):355-62. PubMed ID: 3123445
[TBL] [Abstract][Full Text] [Related]
6. The effects of orchidectomy, estrogens, and cyproterone acetate on plasma testosterone, LH, and FSH concentrations in patients with carcinoma of the prostate.
Varenhorst E; Wallentin L; Carlström K
Scand J Urol Nephrol; 1982; 16(1):31-6. PubMed ID: 6211762
[TBL] [Abstract][Full Text] [Related]
7. Treatment of prostatic cancer with a gonadotropin-releasing hormone agonist analog: acute and long term effects on endocrine functions of testis tissue.
Huhtaniemi I; Nikula H; Rannikko S
J Clin Endocrinol Metab; 1985 Oct; 61(4):698-704. PubMed ID: 2993345
[TBL] [Abstract][Full Text] [Related]
8. [Serum testosterone, dihydrotestosterone, luteinizing hormone and follicle-stimulating hormone versus prostate specific antigen in patients with localized prostate adenocarcinoma who underwent radical prostatectomy. Radioimmunoassays measurements].
Bantis A; Zissimopoulos A; Athanasiadou P; Gonidi M; Agelonidou E; Strataki A; Matthaios D; Tsartsarakis A
Hell J Nucl Med; 2007; 10(1):56-61. PubMed ID: 17450256
[TBL] [Abstract][Full Text] [Related]
9. Testosterone and gonadotrophin profiles in patients on daily or monthly LHRH analogue ICI 118630 (Zoladex) compared with orchiectomy.
Grant JB; Ahmed SR; Shalet SM; Costello CB; Howell A; Blacklock NJ
Br J Urol; 1986 Oct; 58(5):539-44. PubMed ID: 2946356
[TBL] [Abstract][Full Text] [Related]
10. The ratios of serum bioactive/immunoreactive luteinizing hormone and follicle-stimulating hormone in various clinical conditions with increased and decreased gonadotropin secretion: reevaluation by a highly sensitive immunometric assay.
Jaakkola T; Ding YQ; Kellokumpu-Lehtinen P; Valavaara R; Martikainen H; Tapanainen J; Rönnberg L; Huhtaniemi I
J Clin Endocrinol Metab; 1990 Jun; 70(6):1496-505. PubMed ID: 2140831
[TBL] [Abstract][Full Text] [Related]
11. Serum luteinizing hormone (LH) biological activity in castrated patients with cancer of the prostate receiving a pure antiandrogen and in estrogen-pretreated patients treated with an LH-releasing hormone agonist and antiandrogen.
St Arnaud R; Lachance R; Dupont A; Labrie F
J Clin Endocrinol Metab; 1986 Aug; 63(2):297-302. PubMed ID: 3522618
[TBL] [Abstract][Full Text] [Related]
12. [Change of serum adrenal androgens in prostatic cancer patients after bilateral orchidectomy or LHRH agonist treatment].
Oka H; Negoro H; Sugino Y; Iwamura H; Moroi S; Kawakita M
Hinyokika Kiyo; 2003 Sep; 49(9):521-5. PubMed ID: 14598689
[TBL] [Abstract][Full Text] [Related]
13. [Hormonal environment following treatment with a small dose of estrogen--small dose of estrogen alone and in combination with an anti-androgen].
Hayashi T; Taki Y; Ikai K; Hiura M; Kiriyama T
Hinyokika Kiyo; 1987 Jul; 33(7):1035-42. PubMed ID: 2446483
[TBL] [Abstract][Full Text] [Related]
14. [Testosterone, FSH and LH level in the serum of patients with prostatic neoplasms, treated with female hormones].
Weidner W; Krause W; Pust R; Engstfeld J; Rothauge CF
Helv Chir Acta; 1978 Jul; 45(3):287-90. PubMed ID: 701064
[TBL] [Abstract][Full Text] [Related]
15. Steroid hormone concentrations in relation to patient prognosis and prostate tumour grade.
Harper ME; Wilson DW; Jensen HM; Pierrepoint CG; Griffiths K
J Steroid Biochem; 1987; 27(1-3):521-4. PubMed ID: 3121925
[TBL] [Abstract][Full Text] [Related]
16. Targeting FSH in androgen-independent prostate cancer: abarelix for prostate cancer progressing after orchiectomy.
Beer TM; Garzotto M; Eilers KM; Lemmon D; Wersinger EM
Urology; 2004 Feb; 63(2):342-7. PubMed ID: 14972486
[TBL] [Abstract][Full Text] [Related]
17. Response of circulating gonadotropin levels to GnRH agonist treatment in prostatic cancer.
Huhtaniemi I; Venho P; Jacobi G; Rannikko S
J Androl; 1991; 12(1):46-53. PubMed ID: 1901309
[TBL] [Abstract][Full Text] [Related]
18. Hormonal predictors of prostate cancer.
Sofikerim M; Eskicorapci S; Oruç O; Ozen H
Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
[TBL] [Abstract][Full Text] [Related]
19. Pituitary-ovarian relationships preceding the menopause. I. A cross-sectional study of serum follice-stimulating hormone, luteinizing hormone, prolactin, estradiol, and progesterone levels.
Reyes FI; Winter JS; Faiman C
Am J Obstet Gynecol; 1977 Nov; 129(5):557-64. PubMed ID: 910845
[TBL] [Abstract][Full Text] [Related]
20. Hypothalamic-pituitary-gonadal axis in two men with aromatase deficiency: evidence that circulating estrogens are required at the hypothalamic level for the integrity of gonadotropin negative feedback.
Rochira V; Zirilli L; Genazzani AD; Balestrieri A; Aranda C; Fabre B; Antunez P; Diazzi C; Carani C; Maffei L
Eur J Endocrinol; 2006 Oct; 155(4):513-22. PubMed ID: 16990650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
